-
-
-
-
-
-
-
Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Jo
-
-
-
-
-
-
-
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%
-
-
-
-
-
-
-
RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%).
-
-
-
-
-
-
-
RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2017. CONTINUED GROWTH IN SALES +13.1%, OPERATING INCOME +19.0%, NET INCOME +19.9%
-
-
-
-
-
-
-
Recall Financial Results – Half-Year Ended 31 December 2015
-
-
-
-
-
-
-
RECORDATI : SHAREHOLDERS APPROVE THE 2014 ACCOUNTS.
1,198,631 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

